Carmat : Un refinancement attendu dans ces prochains jours
>Une visibilité financière jusqu’à mi-mai - Carmat publie ce matin ses résultats financiers pour l’année 2023. Nous connaissions déjà son chiffre d’affaires à 2,8 M€ sur l’année. Ce chiffre d’affaires correspond à la vente de 17 cœurs artificiels Aeson dont 7 dans le cadre commercial (Allemagne et Italie) et 10 dans le cadre de l’étude EFICAS en France. Le résultat d’exploitation ressort à -52.5 M€ globalement en ligne avec l’année dernière à -51.9 M€ mais inféri...Carmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.